2-{[(2-Aminoethyl)amino](hydroxy)methylidene}-2,3-dihydropyridin-3-one | 103879-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-{[(2-Aminoethyl)amino](hydroxy)methylidene}-2,3-dihydropyridin-3-one
• 英文别名: N-(2-aminoethyl)-3-hydroxypyridine-2-carboxamide
• CAS: 103879-39-6
• 化学式: C₈H₁₁N₃O₂
• mdl: MFCD12772813
• 分子量: 181.19
• InChiKey: ZXTXADWNRQCBJW-UHFFFAOYSA-N

物化性质

• 沸点：
  528.1±45.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  88.2
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS FOR USE IN METHODS OF TREATMENT OF HEMOGLOBIN DISORDERS<br/>[FR] COMPOSITIONS DESTINÉES À ÊTRE UTILISÉES DANS DES MÉTHODES DE TRAITEMENT DES HÉMOGLOBINOPATHIES
  申请人：AKEBIA THERAPEUTICS INC

  公开号：WO2019028150A1

  公开（公告）日：2019-02-07

  The present disclosure relates to hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor compounds and pharmaceutically acceptable salts thereof, to compositions comprising the HIF prolyl hydroxylase inhibitor compounds (e.g., Compound 1), and to methods for treating or preventing hemoglobin disorders such as sickle cell diseases, including sickle cell anemia, hemoglobin SC disease, and sickle β thalassemia, and β thalassemias, including βo-(major) thalassemia and β+-(minor) thalassemia. In addition, the present disclosure relates to specific doses of HIF prolyl hydroxylase inhibitor in treating or preventing hemoglobin disorders such as sickle cell diseases, including sickle cell anemia, hemoglobin SC disease, and sickle β thalassemia, and β thalassemias, including βo-(major) thalassemia and β+-(minor) thalassemia.

  本公开涉及缺氧诱导因子（HIF）脯氨酸羟化酶抑制剂化合物及其药用盐，包括含有HIF脯氨酸羟化酶抑制剂化合物（例如，化合物1）的组合物，以及用于治疗或预防血红蛋白疾病如镰状细胞病，包括镰状细胞贫血、血红蛋白SC病和镰状β地中海贫血，以及β地中海贫血，包括βo-（重型）地中海贫血和β+（轻型）地中海贫血的方法。此外，本公开涉及在治疗或预防血红蛋白疾病如镰状细胞病，包括镰状细胞贫血、血红蛋白SC病和镰状β地中海贫血，以及β地中海贫血，包括βo-（重型）地中海贫血和β+（轻型）地中海贫血中的特定剂量的HIF脯氨酸羟化酶抑制剂。
• Compositions and methods for treating anemia
  申请人：Akebia Therapeutics, Inc.

  公开号：US11324734B2

  公开（公告）日：2022-05-10

  Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

  本文提供了使用HIF脯氨酰羟化酶抑制剂治疗或预防贫血的具体剂量和给药方案，例如继发于或与慢性肾病相关的贫血、继发于或与非透析依赖性慢性肾病相关的贫血、与化疗相关或由化疗引起的贫血或与艾滋病相关的贫血。
• COMPOSITIONS AND METHODS FOR TREATING ANEMIA
  申请人：Akebia Therapeutics Inc.

  公开号：EP3007695A2

  公开（公告）日：2016-04-20
• COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
  申请人：Akebia Therapeutics Inc.

  公开号：EP3096617A1

  公开（公告）日：2016-11-30
• Compositions and Methods for Treating Anemia
  申请人：Akebia Therapeutics, Inc.

  公开号：US20180092892A1

  公开（公告）日：2018-04-05

  Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.